LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

4.67 -4.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.66

Max

4.73

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	16.767 61.417
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+104.49% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 16. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	204M 852M
Iepriekšējā atvēršanas cena	8.78
Iepriekšējā slēgšanas cena	4.67

Ziņu noskaņojums

By Acuity

50%

133 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 16. marts 00:00 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 16. marts 00:00 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 15. marts 23:45 UTC

Tirgus saruna

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026. g. 15. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026. g. 15. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026. g. 15. marts 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026. g. 15. marts 22:37 UTC

Tirgus saruna

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026. g. 15. marts 22:18 UTC

Tirgus saruna

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 03:00 UTC

Galvenie ziņu notikumi

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026. g. 14. marts 15:00 UTC

Galvenie ziņu notikumi

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026. g. 14. marts 02:03 UTC

Peļņas

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026. g. 14. marts 01:32 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026. g. 14. marts 00:29 UTC

Iegādes, apvienošanās, pārņemšana

13D Filings -- Barrons.com

2026. g. 13. marts 22:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026. g. 13. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026. g. 13. marts 22:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026. g. 13. marts 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 20:02 UTC

Tirgus saruna

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026. g. 13. marts 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

104.49% augšup

Prognoze 12 mēnešiem

Vidējais 9.57 USD 104.49%

Augstākais 10 USD

Zemākais 7 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

133 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.